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ABSTRACT
Objective: To examine the differences in the interval
between diagnosis and initiation of treatment among
women with breast cancer in Northern Ireland.
Design: A cross-sectional observational study.
Setting: All breast cancer care patients in the Northern
Ireland Cancer Registry in 2006.
Participants: All women diagnosed and treated for
breast cancer in Northern Ireland in 2006.
Main outcome measure: The number of days
between diagnosis and initiation of treatment for breast
cancer.
Results: The mean (median) interval between
diagnosis and initiation of treatment among public
patients was 19 (15) compared with 14 (12) among
those whose care involved private providers. The
differences between individual public providers were as
marked as those between the public and private sector
—the mean (median) ranging between 14 (12) and
25 (22) days. Multivariate models revealed that the
differences were evident when a range of patient
characteristics were controlled for including cancer
stage.
Conclusions: A relatively small number of women
received care privately in Northern Ireland but
experienced shorter intervals between diagnosis and
initiation of treatment than those who received care
wholly in the public system. The variation among public
providers was as great as that between the public and
private providers. The impact of such differences on
survival and in light of waiting time targets introduced
in Northern Ireland warrants investigation.
INTRODUCTION
Breast cancer incidence rates have risen in
Britain over the past 40 years from 73.8/
100 000 women in 1975 to 126.2/100 000 in
2010.1 As the number of women with the
disease has increased, so too has pressure on
the healthcare system to develop effective
strategies in respect of its management.
While debate continues as to the role that
should be accorded screening as part of the
overall management strategy,2 an early detec-
tion and treatment have been shown in a
number of studies to be signiﬁcant determi-
nants of the cost and outcome.3–6 Previous
work in the Republic of Ireland with respect
to screening7 and in the USA with respect to
treatment8–10 have demonstrated that the
possession of private medical insurance con-
tributes to variations in uptake and services
provided, respectively. Similarly, a work in the
USA with respect to outcomes has shown
these to vary between the public and private
care facilities.11 Evidence from the USA also
suggests that women in possession of private
health insurance have a more favourable
stage of disease at breast cancer diagnosis
than non-insured women.12 While this may
be expected in healthcare systems where
there exists a signiﬁcant role for private
ﬁnance or provision (in the USA and Ireland
approximately 50% of the adult population
hold private medical insurance),13 14 in
systems where private ﬁnance and/or deliv-
ery of core services are the exception rather
than the norm, one might not expect policy-
makers to be as sanguine as to the existence
of such differences or for such difference to
be evident as a result. As healthcare budgets
come under increasing pressure, so evidence
of an apparent superiority of private medi-
cine in contexts such as the UK may receive
keen attention among policymakers
Strengths and limitations of this study
▪ The study was population rather than
sample based.
▪ The study was able to control for a limited
number of confounding variables.
▪ The study uses data that precedes recent initia-
tives aimed at addressing waiting time targets
for patients with cancer in Northern Ireland.
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struggling to provide quality services in an efﬁcient
manner. While evidence that delays in initiation of treat-
ment are material in a clinical sense are mixed15 16 that
delays may well impact on anxiety levels among patients
is evident.17 In this paper, we examine the differences in
the interval between diagnosis and initiation of care in
patients with breast cancer among the private and
public providers in Northern Ireland. We examine the
intervals between diagnosis and treatment among and
between the public and private providers and discuss the
implications this may have for the commissioning of
services.
METHODS
Data for all women diagnosed with breast cancer in
Northern Ireland in 2006 were obtained from the
Northern Ireland Cancer Registry (NICR). The Registry is
a state-funded body that registers all cancer diagnoses in
Northern Ireland and contains a range of data on the
patient, their diagnosis and treatment. A total of 951
women were recorded by the registry as being diagnosed
with breast cancer in 2006. Data on 848i women in the
NICR were extracted for analysis. Data included the details
on the care provider (healthcare and social care Trust) in
which the woman was treated and whether the woman
had a record of being diagnosed or treated at any stage of
the care pathway privately. In addition, data on the cancer
stage (I–IV), the woman’s age at diagnosis, the socio-
economic deprivation score for the area in which she
resided, whether she resided in a rural or urban area,
whether or not she experienced comorbid conditions and
the number of symptoms experienced. Data on the source
of the referral and the Trust where the woman presented
were also extracted. The complete details of all variables
are presented in online supplementary appendix 1. The
interval used here is the duration time between diagnosis
of breast cancer and the initiation of any treatment, that is,
pre-treatment in terms of the Aarhus Statement.18
A Cox’s proportional hazards regression model19 was
used to examine whether women who were seen at any
stage of their cancer journey privately had a different inter-
val between diagnosis and initiation of treatment when
other variables were controlled, than women who were
dealt with entirely within the publicly funded system.
Duration was measured in days. Women whose treatment
was initiated on the same day as diagnosis were treated as
having an interval between treatment and diagnosis of 1.
The secondary analyses examined the variation among the
public providers using a Cox regression model.19 The pro-
portional hazards assumption for the Cox regression
model is tested using Schoenfeld residuals.20
RESULTS
In table 1, descriptive statistics on a range of variables
for women included in the Cox proportional hazards
regression model are presented.
A total of 759 women were seen solely in public hospi-
tals and 89 at some stage in private hospitals. The mean
duration between diagnosis and initiation of treatment
Table 1 Descriptive statistics
Variable
Age Percentage of obs N Variable Percentage of obs N
40 or under 7.1 60 Stage at diagnosis:stage 1 30.4 258
41–50 20.6 175 Stage 2 43.6 370
51–55 11.4 97 Stage 3 19.6 166
56–60 13.3 113 Stage 4 6.4 54
60–65 12.3 104 Average number of symptoms 2
66–70 8.4 71 Deprivation score: most deprived (1) 19.6 166
Age71 or greater 27 228 Quintile 2 19.3 164
Trust of presentation:
Breast screening unit
16.8 143 Quintile 3 18.8 159
Belfast HSCT 24.4 207 Quintile 4 22.5 191
Northern HSCT 12.8 109 Least deprived (5) 19.8 168
Private 10.5 89 Have a comorbidity 72 612
South Eastern HSCT 12 100 Source of referral—GP 74 625
Southern HSCT 11.56 102 Referral source-action cancer 2 19
Western HSCT
Area of residence
11 98 Referral source—breast screening unit 17 143
Urban 64 542 Referral source—other 6.9 58
GP, general practitioner; HSCT, Health and Social Care Trust.
i
Fifty-one were dropped from the analysis as there was a negative value
for the number of days between the date of diagnosis and the
beginning of treatment. Two outliers were excluded from the analysis
as their treatments were signiﬁcantly delayed due to other life-limiting
diseases. One related to a private patient with a duration of 561 days,
and another of a public patient with a duration of 223 days. An
additional 50 women were excluded as the stage at diagnosis was
unknown and inclusion in the models violated the proportional
hazards assumptions for the Cox proportional hazards regression
model.
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for women seen at some stage in private hospitals was
14 days and that for those seen solely in publicly funded
hospitals is 19 days. The difference in the interval
between diagnosis and initiation of treatment was statis-
tically signiﬁcant before other variables were controlled
for, p<0.01. The differences in the percentages of
private versus public patients in terms of the intervals
between diagnosis and initiation of treatment are
reported in table 2 at various durations.
Table 3 shows each of the number of women in the
dataset by trust in which they lived and the trust in
which they presented, for example, 179 women diag-
nosed with breast cancer in 2006 resided in the Belfast
Trust area but 237 women presented through the Belfast
Trust. As illustrated the Trust with the highest number
opting for private healthcare is the South Eastern
Health and Social Care Trust (HSCT) with the lowest
number coming from the Western Trust.
Figure 1 illustrates the variation in interval for both
groups of patients. The y-axis represents the number of days
between diagnosis and treatment; the whiskers plot the CI.
The results from Cox’s proportional hazards regres-
sion model in which we focus on the distinction
between public and private controlling for a range of
variables—including age, stage, source of referral,
comorbid status and deprivation score—are presented
in table 4. Coefﬁcients in the table may be interpreted
as follows: if the coefﬁcient is greater than 1, treatment
is likely to be initiated sooner after diagnosis; if the coef-
ﬁcient is less than 1, the interval between diagnosis and
initiation of treatment is likely to be longer. As can be
seen, controlling for confounding variables, women
diagnosed or treated at any stage privately are likely to
have a shorter interval between diagnosis and initiation
of treatment than those whose diagnosis and treatment
are wholly within the public system. The p value for the
Schoenfeld residual test is presented at the end of
table 3.19 Obtaining a p value greater than 0.05 indicates
that the proportional hazards assumption for the Cox
regression model is not violated.
Examining the variations in the interval between diag-
nosis and initiation of treatment among providers
reveals that, on an average, the interval was 15 days for
Belfast HSCT (n=207), 18 days for the Northern HSCT
(n=109), 14 days for private hospitals (n=89) or the
South-Eastern HSCT n=(100), 25 days for the Southern
HSCT (n=102), 19 days for the Western HSCT (n=98)
and 24 days for the breast screening programme
(n=143). This indicates wide variations among publicly
funded care providers. In table 5, results of a Cox regres-
sion that controls for individual trusts are reported, as
well as confounding variables are presented. As can be
seen while the coefﬁcient on private hospitals remains
Table 2 Duration between diagnosis of breast cancer
and beginning of treatment
Number of days
between diagnosis and
treatment of breast
cancer
Public
patients
(N=759)
Private
patients
(N=89)
Treatment initiated on the
same day
4% 5%
Treatment initiated
between 1 and 10 days
after diagnosis
27% 41%
Treatment initiated
between 11 and 15 days
after diagnosis
23% 20.5%
Treatment initiated
between 16 and 25 days
after diagnosis
23.4% 20.5%
Treatment initiated
between 26and 75 days
after diagnosis
22% 13%
Treatment initiated
between 76 and 121 days
after diagnosis
0.6% 0%
Average time between
diagnosis and initiation of
treatment
19 days 14 days
Median time between
diagnosis and initiation of
treatment
15 days 12 days
10th centile 5 days 3 days
25th centile 9 days 6.5 days
50th centile 15 days 12 days
75th centile 24 days 18 days
90th centile 36 days 28 days
95th centile 48 days 33 days
Table 3 Trust of residence and trust of presentation
Trust of residence
Trust of presentation
Belfast BSU Northern Private South-Eastern Southern Western Total
Belfast 108 20 0 16 35 0 0 179
Northern 53 36 123 28 5 4 4 253
South Eastern 57 26 1 30 76 0 0 190
Southern 18 37 2 17 3 113 2 192
Western 1 29 0 5 0 1 99 135
Total 237 148 126 96 119 118 105 949*
*Trust of presentation was not recorded for two women in the sample, they are not included in table 3.
BSU, breast screening unit.
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signiﬁcant, so too is that on several of the publicly
funded care providers.
DISCUSSION
In the interests of brevity, we focus our discussion on the
impact of public versus private care on the interval
between diagnosis and initiation of treatment as well as
among the public sector providers. The differences are
evident between patients whose entire care was within
the public sector and those who were seen at some point
in the private sector. That private medicine (funding or
provision) should impact on care in a mixed healthcare
system is unsurprising. Self-interest would suggest the
reason individuals hold private medical insurance is
because of the superior service—including the speed
with which individual’s treatment might be initiated21—
it affords and private providers operate because there
exists an effective demand for the services they provide.
As noted, the previous studies in the area of breast
cancer have demonstrated the existence of difference
whether in service uptake, provision or outcome7 10 11 in
such systems. That differences in terms of the speed
with which care is initiated appear to exist between the
public and private sectors in a country whose publicly
funded healthcare system extols equality of access based
on need, and not the ability to pay is not perhaps what
one might expect. With speciﬁc regard to the interval
between diagnosis and initiation of treatment, general
concerns have indeed been explicitly referenced by the
Department of Health.17 Crucially though these have
focused on variations per se and not on variations
between public and private providers. This study has
clearly demonstrated that such concerns (at least in
2006) were justiﬁed in the Northern Ireland.
Importantly, even though there were differences between
the private and public providers (when confounding
Figure 1 Duration times for private and public patients
between diagnosis and treatment of breast cancer, all stages.
Table 4 Cox’s proportional hazards regression model
output
Variable N=845† HR
Urban/rural 1.045 (0.075)
Age 41–50 1.062 (0.16)
Age 51–55 0.894 (0.148)
Age 56–60 1.181 (0.19)
Age 60–65 1.033 (0.169)
Age 66–70 1.126 (0.211)
Age 71 or greater 1.154 (0.17)
Have a comorbidity 0.996 (0.005)
Stage 2 1.04 (0.082)
Stage 3 1.025 (0.108)
Stage 4 0.956 (0.152)
Number of symptoms 0.982 (0.019)
Quintile 2 0.878 (0.093)
Quintile 3 0.873 (0.097)
Quintile 4 0.839 (0.09)
Least deprived 1.116 (0.123)
Breast screening unit 0.647*** (0.066)
Action cancer 1.158 (0.217)
Other 0.889 (0.151)
Individuals seen privately at some
stage along the treatment pathway
1.358** (0.178)
Schoenfeld residual test p value <0.05
Numbers in parentheses are SEs.
*, 90% significance level; **, 95% significance level;
***, 99% significance level.
†Source of referral is unknown for three observations which are
excluded from the model displayed in table 4.
Table 5 Cox’s proportional hazards regression model
output—trust of presentation
Variable (N=848) HR
Urban/rural 1.125 (0.082)
Age 41–50 1.079 (0.164)
Age 51–55 0.92 (0.149)
Age 56–60 1.21 (0.195)
Age 60–65 1.024 (0.172
Age 66–70 1.167 (0.222)
Age 71 or greater 1.128 (0.169)
Have a comorbidity 0.995 (0.005)
Stage 2 1.017 (0.08)
Stage 3 0.972 (0.109)
Stage 4 0.909 (0.147)
Number of symptoms 0.988 (0.019)
Quintile 2 0.885 (0.093)
Quintile 3 0.849 (0.095)
Quintile 4 0.8** (0.088)
Least deprived 0.96 (0.108)
Belfast HSCT 0.962 (0.15)
Northern HSCT 0.732* (0.119)
Breast screening unit 0.475*** (0.074)
South-Eastern HSCT 0.957 (0.156)
Southern HSCT 0.464*** (0.076)
Western HSCT 0.68** (0.113)
Schoenfeld residual test p value <0.05
Numbers in parentheses are SEs.
*, 90% significance level; **, 95% significance level;
***, 99% significance level.
HSCT, Health and Social Care Trust.
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variables are controlled for), the dichotomy between the
public and private provision is false in the sense that best
practice among public providers was on a par with that in
the private sector. Poor performance among some public
providers was not evident among all of them. It is unclear
whether the difference between the best and worst per-
forming providers in terms of the interval in the initiation
of treatment was material with respect to the outcome,
though others have found delays may be a source of
anxiety to some patients18 22 and as noted with respect to
survival.16 In their investigation into the effect of waiting
times between localised breast cancer diagnosis and treat-
ment, Redaniel et al15 found that the duration times have
a very little impact on survival. However, as highlighted by
Paul et al,22 longer interval times can have negative psy-
chological impacts on patients with cancer. This also
raises the question of the effect of longer duration times
on non-localised breast cancer. Our results show that
there is no stage differential in the interval between diag-
nosis and initiation of treatment.
The cost and outcomes do not form part of the analysis
undertaken and no inference with respect to these is
made. The difference in the speed with which the system
responds may nevertheless be taken as a valid indicator of
quality. What might constitute an appropriate policy
response to such delays, this study suggests, will depend
on the particular circumstances that explain poor per-
formance in the case of individual providers. These may
relate to the stafﬁng issues unique to the period studied,
other capacity issues or broader managerial deﬁciencies.
That the issue is public sector provision per se though is
clearly not the case. As public expectations rise and
healthcare budgets come under increasing pressure,
debate as to how best to deliver care in breast cancer and
other services will intensify. Privatisation will inevitably be
mooted by some as a solution. These results, however,
indicate that with respect to breast cancer services, there
is no reason to believe it offers a superior service to that
which can be delivered by the public sector.
Since 2006, waiting time targets for patients with cancer
have been introduced in Northern Ireland. Whether this
has impacted on the speed with which treatment is
initiated (ie, delay in receiving treatment after a positive
diagnosis) or differences among and between public and
private providers in this regard require further examin-
ation. What, if any, impact such delays or failure to reach
targets may have had on survival and cost of care are also
areas that seem worthy of further examination.
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